Table 3.

Multivariable analysis of FRα H-score with invasive disease-free and overall survival.

	IDFS		OS
	HR (95% CI)	P-value	HR (95% CI)	P-value
Age
<45	1.0 (ref)		1.0 (ref)
45–54.3	0.65 (0.39–1.08)	0.09	0.62 (0.33–1.17)	0.14
54.4–65.7	0.55 (0.27–1.10)	0.09	0.80 (0.36–1.77)	0.58
65.8–88.4	0.73 (0.35–1.53)	0.41	1.29 (0.58–2.88)	0.53
Menopausal status
Pre/Peri	1.0 (ref)		1.0 (ref)
Post	1.66 (0.95–2.91)	0.08	2.00 (1.02–3.91)	0.04
Tumor size
T1 (0.1–2.0 cm)	1.0 (ref)		1.0 (ref)
T2 (2.1–5.0 cm)	1.17 (0.81–1.71)	0.4	1.35 (0.92–1.96)	0.12
T3/4 (5.1+ cm)	1.84 (0.92–3.69)	0.08	1.90 (0.97–3.74)	0.06
Nodal status
N0	1.0 (ref)	0.008	1.0 (ref)
N1	1.90 (1.18–3.04)	0.008	2.72 (1.67–4.43)	<0.001
N2	2.33 (1.27–4.29)	0.007	3.54 (1.96–6.37)	<0.001
N3	6.02 (3.05–11.90)	<0.001	8.95 (4.65–17.24)	<0.001
NX	2.44 (0.53–11.36)	0.25	3.77 (1.21–11.74)	0.02
Histology
Invasive carcinoma NST	1.0 (ref)		1.0 (ref)
Metaplastic carcinoma NST	0.82 (0.43–1.58)	0.55	0.50 (0.23–1.09)	0.08
Ca. with apocrine differentiation	0.53 (0.22–1.28)	0.16	0.38 (0.16–0.91)	0.03
Ca. with medullary features	0.83 (0.49–1.41)	0.49	0.80 (0.47–1.37)	0.42
Nottingham grade
1	1.0 (ref)		1.0 (ref)
2	1.10 (0.23–5.27)	0.9	1.21 (0.25–5.91)	0.81
3	0.54 (0.11–2.55)	0.44	0.83 (0.18–3.84)	0.81
Ki-67 grouping
≤15%	1.0 (ref)		1.0 (ref)
15.1–30%	0.94 (0.51–1.72)	0.83	0.78 (0.42–1.45)	0.43
>30%	1.28 (0.77–2.11)	0.34	0.93 (0.58–1.49)	0.75
Stromal TILs (per 10% increment)	0.86 (0.78–0.95)	0.003	0.86 (0.78–0.95)	0.004
FRα H-score
0	1.0 (ref)		1.0 (ref)
>0	0.63 (0.44–0.91)	0.01	0.87 (0.60–1.26)	0.46
Adjuvant chemotherapy
No	1.0 (ref)		1.0 (ref)
Yes	0.61 (0.39–0.95)	0.03	0.44 (0.28–0.71)	<0.001
Unknown	1.27 (0.34–4.73)	0.73	1.07 (0.34–3.33)	0.91
Adjuvant radiotherapy
No	1.0 (ref)		1.0 (ref)
Yes	0.87 (0.51–1.48)	0.62	0.85 (0.50–1.43)	0.53
Unknown	1.12 (0.28–4.56)	0.87	0.87 (0.28–2.68)	0.81

NST no special type, FRα folate receptor alpha.